Bicyclic Boronate VNRX-5133 Inhibits Metallo- And Serine-β-Lactamases

Journal of Medicinal Chemistry

Volumn 62, Issue 18, 2019, Pages 8544-8556

  Krajnc, Alen ^a   Brem, Jürgen ^a   Hinchliffe, Philip ^b   Calvopiña, Karina ^a   Panduwawala, Tharindi D ^a   Lang, Pauline A ^a   Kamps, Jos J A G ^a   Tyrrell, Jonathan M ^c   Widlake, Emma ^c   Saward, Benjamin G ^a   Walsh, Timothy R ^c   Spencer, James ^b   Schofield, Christopher J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; CEFEPIME; MEROPENEM; METALLO BETA LACTAMASE; SERINE BETA LACTAMASE; TANIBORBACTAM; UNCLASSIFIED DRUG; VABORBACTAM; VNRX 5133; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; BORON; BRIDGED BICYCLO COMPOUNDS; OXYGEN; SOLVENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; COMPARATIVE STUDY; CRYSTALLOGRAPHY; DRUG BINDING; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME INHIBITION; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; X RAY CRYSTALLOGRAPHY; CHEMISTRY; DRUG DESIGN; DRUG EFFECT; ENZYME ACTIVE SITE; HUMAN; IC50; MICROBIAL SENSITIVITY TEST; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ANTI-INFECTIVE AGENTS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; BORON; BRIDGED BICYCLO COMPOUNDS; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ESCHERICHIA COLI; HUMANS; INHIBITORY CONCENTRATION 50; KLEBSIELLA PNEUMONIAE; MAGNETIC RESONANCE SPECTROSCOPY; MICROBIAL SENSITIVITY TESTS; OXYGEN; SOLVENTS;

EID: 85072687235     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.9b00911     Document Type: Article

References (60)

1. Munita, J. M.; Arias, C. A. Mechanisms of Antibiotic Resistance. Microbiol. Spectr. 2016, 4, 42 10.1128/microbiolspec.VMBF-0016-2015
2. Majiduddin, F. K.; Materon, I. C.; Palzkill, T. G. Molecular analysis of beta-lactamase structure and function. Int. J. Med. Microbiol. 2002, 292, 127-137, 10.1078/1438-4221-00198
3. Leigh, D. A.; Bradnock, K.; Marriner, J. M. Augmentin (amoxycillin and clavulanic acid) therapy in complicated infections due to beta-lactamase producing bacteria. J. Antimicrob. Chemother. 1981, 7, 229-236, 10.1093/jac/7.3.229
4. Reading, C.; Cole, M. Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus. Antimicrob. Agents Chemother. 1977, 11, 852-857, 10.1128/AAC.11.5.852
5. Benson, J. M.; Nahata, M. C. Sulbactam/ampicillin, a new beta-lactamase inhibitor/beta-lactam antibiotic combination. Drug Intell. Clin. Pharm. 1988, 22, 534-541, 10.1177/106002808802200702
6. Gutmann, L.; Kitzis, M. D.; Yamabe, S.; Acar, J. F. Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases. Antimicrob. Agents Chemother. 1986, 29, 955-957, 10.1128/AAC.29.5.955
7. Papp-Wallace, K. M.; Endimiani, A.; Taracila, M. A.; Bonomo, R. A. Carbapenems: past, present, and future. Antimicrob. Agents Chemother. 2011, 55, 4943-4960, 10.1128/AAC.00296-11
8. Bush, K.; Bradford, P. A. Interplay between beta-lactamases and new beta-lactamase inhibitors. Nat. Rev. Microbiol. 2019, 17, 295-306, 10.1038/s41579-019-0159-8
9. Palzkill, T. Metallo-beta-lactamase structure and function. Ann. N. Y. Acad. Sci. 2013, 1277, 91-104, 10.1111/j.1749-6632.2012.06796.x
10. Walsh, T. R. Emerging carbapenemases: a global perspective. Int. J. Antimicrob. Agents 2010, 36, S8-S14, 10.1016/S0924-8579(10)70004-2
11. Zhanel, G. G.; Lawson, C. D.; Adam, H.; Schweizer, F.; Zelenitsky, S.; Lagace-Wiens, P. R.; Denisuik, A.; Rubinstein, E.; Gin, A. S.; Hoban, D. J.; Lynch, J. P., 3rd; Karlowsky, J. A. Ceftazidime-avibactam: a novel cephalosporin/beta-lactamase inhibitor combination. Drugs 2013, 73, 159-177, 10.1007/s40265-013-0013-7
12. Ehmann, D. E.; Jahic, H.; Ross, P. L.; Gu, R. F.; Hu, J.; Kern, G.; Walkup, G. K.; Fisher, S. L. Avibactam is a covalent, reversible, non-beta-lactam beta-lactamase inhibitor. Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 11663-11668, 10.1073/pnas.1205073109
13. Abboud, M. I.; Damblon, C.; Brem, J.; Smargiasso, N.; Mercuri, P.; Gilbert, B.; Rydzik, A. M.; Claridge, T. D. W.; Schofield, C. J.; Frère, J.-M. Interaction of Avibactam with Class B Metallo-β-Lactamases. Antimicrob. Agents Chemother. 2016, 60, 5655-5662, 10.1128/AAC.00897-16
14. Lohans, C. T.; Brem, J.; Schofield, C. J. New Delhi Metallo-β-Lactamase 1 Catalyzes Avibactam and Aztreonam Hydrolysis. Antimicrob. Agents Chemother. 2017, 61, e01224-e01217, 10.1128/AAC.01224-17
15. Gareth, W.; Langley, R. C.; Tyrrell, J. M.; Hinchliffe, P.; Calvopiña, K.; Tooke, C.; Widlake, E.; Dowson, C. G.; Spencer, J.; Walsh, T. R.; Schofield, C. J.; Brem, J. Profiling Interactions of Vaborbactam with Metallo-β-Lactamases. Bioorg. Med. Chem. Lett. 2019, 29, 1981-1984, 10.1016/j.bmcl.2019.05.031
16. Field-Smith, A.; Morgan, G. J.; Davies, F. E. Bortezomib (Velcade trade mark) in the Treatment of Multiple Myeloma. Ther. Clin. Risk Manage. 2006, 2, 271-279, 10.2147/tcrm.2006.2.3.271
17. Morandi, F.; Caselli, E.; Morandi, S.; Focia, P. J.; Blazquez, J.; Shoichet, B. K.; Prati, F. Nanomolar inhibitors of AmpC beta-lactamase. J. Am. Chem. Soc. 2003, 125, 685-695, 10.1021/ja0288338
18. Werner, J. P.; Mitchell, J. M.; Taracila, M. A.; Bonomo, R. A.; Powers, R. A. Exploring the potential of boronic acids as inhibitors of OXA-24/40 beta-lactamase. Protein Sci. 2017, 26, 515-526, 10.1002/pro.3100
19. Rojas, L. J.; Taracila, M. A.; Papp-Wallace, K. M.; Bethel, C. R.; Caselli, E.; Romagnoli, C.; Winkler, M. L.; Spellberg, B.; Prati, F.; Bonomo, R. A. Boronic Acid Transition State Inhibitors Active against KPC and Other Class A beta-Lactamases: Structure-Activity Relationships as a Guide to Inhibitor Design. Antimicrob. Agents Chemother. 2016, 60, 1751-1759, 10.1128/AAC.02641-15
20. Strynadka, N. C.; Martin, R.; Jensen, S. E.; Gold, M.; Jones, J. B. Structure-based design of a potent transition state analogue for TEM-1 beta-lactamase. Nat. Struct. Mol. Biol. 1996, 3, 688-695, 10.1038/nsb0896-688
21. Ness, S.; Martin, R.; Kindler, A. M.; Paetzel, M.; Gold, M.; Jensen, S. E.; Jones, J. B.; Strynadka, N. C. Structure-based design guides the improved efficacy of deacylation transition state analogue inhibitors of TEM-1 beta-Lactamase. Biochemistry 2000, 39, 5312-5321, 10.1021/bi992505b
22. Diaz, D. B.; Yudin, A. K. The versatility of boron in biological target engagement. Nat. Chem. 2017, 9, 731-742, 10.1038/nchem.2814
23. Krajnc, A.; Lang, P. A.; Panduwawala, T. D.; Brem, J.; Schofield, C. J. Will morphing boron-based inhibitors beat the beta-lactamases?. Curr. Opin. Chem. Biol. 2019, 50, 101-110, 10.1016/j.cbpa.2019.03.001
24. Hecker, S. J.; Reddy, K. R.; Totrov, M.; Hirst, G. C.; Lomovskaya, O.; Griffith, D. C.; King, P.; Tsivkovski, R.; Sun, D.; Sabet, M.; Tarazi, Z.; Clifton, M. C.; Atkins, K.; Raymond, A.; Potts, K. T.; Abendroth, J.; Boyer, S. H.; Loutit, J. S.; Morgan, E. E.; Durso, S.; Dudley, M. N. Discovery of a Cyclic Boronic Acid beta-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases. J. Med. Chem. 2015, 58, 3682-3692, 10.1021/acs.jmedchem.5b00127
25. Dhillon, S. Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections. Drugs 2018, 78, 1259-1270, 10.1007/s40265-018-0966-7
26. Lomovskaya, O.; Sun, D.; Rubio-Aparicio, D.; Nelson, K.; Tsivkovski, R.; Griffith, D. C.; Dudley, M. N. Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob. Agents Chemother. 2017, 61, e01443-e01417, 10.1128/AAC.01443-17
27. Brem, J.; Cain, R.; Cahill, S.; McDonough, M. A.; Clifton, I. J.; Jiménez-Castellanos, J.-C.; Avison, M. B.; Spencer, J.; Fishwick, C. W. G.; Schofield, C. J. Structural basis of metallo-β-lactamase, serine-β-lactamase and penicillin-binding protein inhibition by cyclic boronates. Nat. Commun. 2016, 7, 12406 10.1038/ncomms12406
28. Cahill, S. T.; Cain, R.; Wang, D. Y.; Lohans, C. T.; Wareham, D. W.; Oswin, H. P.; Mohammed, J.; Spencer, J.; Fishwick, C. W. G.; McDonough, M. A.; Schofield, C. J.; Brem, J. Cyclic Boronates Inhibit All Classes of β-Lactamases. Antimicrob. Agents Chemother. 2017, 61, e02260-e02216, 10.1128/AAC.02260-16
29. Cahill, S. T.; Tyrrell, J. M.; Navratilova, I. H.; Calvopina, K.; Robinson, S. W.; Lohans, C. T.; McDonough, M. A.; Cain, R.; Fishwick, C. W. G.; Avison, M. B.; Walsh, T. R.; Schofield, C. J.; Brem, J. Studies on the inhibition of AmpC and other beta-lactamases by cyclic boronates. Biochim. Biophys. Acta, Gen. Subj. 2019, 1863, 742-748, 10.1016/j.bbagen.2019.02.004
30. Burns, C. J.; Daigle, D.; Liu, B.; McGarry, D.; Pevear, D. C.; Trout, R. E. L. Beta-Lactamase Inhibitors. WO Patent WO 2014/089365 A1.
31. Mushtaq, S.; Vickers, A.; Woodford, N.; Livermore, D. M. Potentiation of cefepime by the boronate VNRX-5133 versus gram-negative bacteria with known β-lactamases; European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Madrid: Spain, 2018.
32. Hackel Meredith, D. S. Antimicrobial Activity of Cefepime in Combination with VNRX-5133 Against a Global 2018 Surveillance Collection of Clinical Isolates; European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam: The Netherlands, 2019.
33. Hamrick, J. C.; Chatwin, C. L.; John, K. J.; Pevear, D. C.; Burns, C. J.; Xerri, L. The Ability of Broad-spectrum β-Lactamase Inhibitor Vnrx-5133 to Restore Bactericidal Activity of Cefepime in Enterobacteriaceae and P. aeruginosa-Expressing Ambler Class A, B, C and D Enzymes is Demonstrated Using Time-Kill Kinetics; European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Madrid: Spain, 2018.
34. Matteson, D. S. Boronic esters in asymmetric synthesis. J. Org. Chem. 2013, 78, 10009-10023, 10.1021/jo4013942
35. Matteson, D. S.; Majumdar, D. Homologation of Boronic Esters to Alpha-Chloro Boronic Esters. Organometallics 1983, 2, 1529-1535, 10.1021/om50005a008
36. Matteson, D. S.; Ray, R. Directed Chiral Synthesis with Pinanediol Boronic Esters. J. Am. Chem. Soc. 1980, 102, 7590-7591, 10.1021/ja00545a046
37. Coste, J.; Le-Nguyen, D.; Castro, B. PyBOP: A new peptide coupling reagent devoid of toxic by-product. Tetrahedron Lett. 1990, 31, 205-208, 10.1016/S0040-4039(00)94371-5
38. van Berkel, S. S.; Brem, J.; Rydzik, A. M.; Salimraj, R.; Cain, R.; Verma, A.; Owens, R. J.; Fishwick, C. W.; Spencer, J.; Schofield, C. J. Assay platform for clinically relevant metallo-beta-lactamases. J. Med. Chem. 2013, 56, 6945-6953, 10.1021/jm400769b
39. Daigle, D.; Hamrick, J.; Chatwin, C.; Kurepina, N.; Kreiswirth, B. N.; Shields, R. K.; Oliver, A.; Clancy, C. J.; Nguyen, M.-H.; Pevear, D.; Xerri, L. 1370. Cefepime/VNRX-5133 Broad-Spectrum Activity Is Maintained Against Emerging KPC-and PDC-Variants in Multidrug-Resistant K. pneumoniae and P. aeruginosa. Open Forum Infect. Dis. 2018, 5, S419-S420, 10.1093/ofid/ofy210.1201
40. van den Akker, F.; Bonomo, R. A. Exploring Additional Dimensions of Complexity in Inhibitor Design for Serine β-Lactamases: Mechanistic and Intra-and Inter-molecular Chemistry Approaches. Front. Microbiol. 2018, 9, 1-622, 10.3389/fmicb.2018.00622
41. Calvopiña, K.; Hinchliffe, P.; Brem, J.; Heesom, K. J.; Johnson, S.; Cain, R.; Lohans, C. T.; Fishwick, C. W. G.; Schofield, C. J.; Spencer, J.; Avison, M. B. Structural/mechanistic insights into the efficacy of nonclassical beta-lactamase inhibitors against extensively drug resistant Stenotrophomonas maltophilia clinical isolates. Mol. Microbiol. 2017, 106, 492-504, 10.1111/mmi.13831
42. Inglis, S. R.; Woon, E. C. Y.; Thompson, A. L.; Schofield, C. J. Observations on the Deprotection of Pinanediol and Pinacol Boronate Esters via Fluorinated Intermediates. J. Org. Chem. 2010, 75, 468-471, 10.1021/jo901930v
43. Zhang, H.; Ma, G.; Zhu, Y.; Zeng, L.; Ahmad, A.; Wang, C.; Pang, B.; Fang, H.; Zhao, L.; Hao, Q. Active-Site Conformational Fluctuations Promote the Enzymatic Activity of NDM-1. Antimicrob. Agents Chemother. 2018, 62, e01579-e01518, 10.1128/AAC.01579-18
44. Ullah, J. H.; Walsh, T. R.; Taylor, I. A.; Emery, D. C.; Verma, C. S.; Gamblin, S. J.; Spencer, J. The crystal structure of the L1 metallo-β-lactamase from Stenotrophomonas maltophilia at 1.7 å resolution11 Edited by K. Nagai. J. Mol. Biol. 1998, 284, 125-136, 10.1006/jmbi.1998.2148
45. Hopkinson, R. J.; Tumber, A.; Yapp, C.; Chowdhury, R.; Aik, W.; Che, K. H.; Li, X. S.; Kristensen, J. B. L.; King, O. N. F.; Chan, M. C.; Yeoh, K. K.; Choi, H.; Walport, L. J.; Thinnes, C. C.; Bush, J. T.; Lejeune, C.; Rydzik, A. M.; Rose, N. R.; Bagg, E. A.; McDonough, M. A.; Krojer, T.; Yue, W. W.; Ng, S. S.; Olsen, L.; Brennan, P. E.; Oppermann, U.; Muller-Knapp, S.; Klose, R. J.; Ratcliffe, P. J.; Schofield, C. J.; Kawamura, A. 5-Carboxy-8-hydroxyquinoline is a Broad Spectrum 2-Oxoglutarate Oxygenase Inhibitor which Causes Iron Translocation. Chem. Sci. 2013, 4, 3110-3117, 10.1039/c3sc51122g
46. Tierney, D. L.; Schenk, G. X-ray absorption spectroscopy of dinuclear metallohydrolases. Biophys. J. 2014, 107, 1263-1272, 10.1016/j.bpj.2014.07.066
47. Aitha, M.; Al-Adbul-Wahid, S.; Tierney, D. L.; Crowder, M. W. Probing substrate binding to the metal binding sites in metallo-β-lactamase L1 during catalysis. MedChemComm 2016, 7, 194-201, 10.1039/C5MD00358J
48. Gonzalez, M. M.; Kosmopoulou, M.; Mojica, M. F.; Castillo, V.; Hinchliffe, P.; Pettinati, I.; Brem, J.; Schofield, C. J.; Mahler, G.; Bonomo, R. A.; Llarrull, L. I.; Spencer, J.; Vila, A. J. Bisthiazolidines: A Substrate-Mimicking Scaffold as an Inhibitor of the NDM-1 Carbapenemase. ACS Infect. Dis. 2015, 1, 544-554, 10.1021/acsinfecdis.5b00046
49. Garau, G.; Bebrone, C.; Anne, C.; Galleni, M.; Frère, J.-M.; Dideberg, O. A Metallo-β-lactamase Enzyme in Action: Crystal Structures of the Monozinc Carbapenemase CphA and its Complex with Biapenem. J. Mol. Biol. 2005, 345, 785-795, 10.1016/j.jmb.2004.10.070
50. Wu, S.; Xu, D.; Guo, H. QM/MM Studies of Monozinc β-Lactamase CphA Suggest That the Crystal Structure of an Enzyme-Intermediate Complex Represents a Minor Pathway. J. Am. Chem. Soc. 2010, 132, 17986-17988, 10.1021/ja104241g
51. Vercheval, L.; Bauvois, C.; di Paolo, A.; Borel, F.; Ferrer, J.-L.; Sauvage, E.; Matagne, A.; Frère, J.-M.; Charlier, P.; Galleni, M.; Kerff, F. Three factors that modulate the activity of class D β-lactamases and interfere with the post-translational carboxylation of Lys70. Biochem. J. 2010, 432, 495-506, 10.1042/BJ20101122
52. Abdelraouf, K.; Abuhussain, S. A.; Nicolau, D. P. 1405. Efficacy of the Human-Simulated Regimen (HSR) of Cefepime (FEP)/VNRX-5133 Combination Against Serine β-Lactamase-Producing Gram-negative Bacteria in the Neutropenic Murine Thigh Infection Model. Open Forum Infect. Dis. 2018, 5, S432-S433, 10.1093/ofid/ofy210.1236
53. Geibel, B.; Dowell, J.; Dickerson, D.; Henkel, T. 1401. A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single and Repeat Doses of VNRX-5133 in Healthy Subjects. Open Forum Infect. Dis. 2018, 5, S431, 10.1093/ofid/ofy210.1232
54. Hackel, M.; Sahm, D. 1360. Antimicrobial Activity of Cefepime in Combination with VNRX-5133 Against a Global Collection of Enterobacteriaceae Including Resistant Phenotypes. Open Forum Infect. Dis. 2018, 5, S416-S417, 10.1093/ofid/ofy210.1191
55. Demetriades, M.; Leung, I. K.; Chowdhury, R.; Chan, M. C.; McDonough, M. A.; Yeoh, K. K.; Tian, Y. M.; Claridge, T. D.; Ratcliffe, P. J.; Woon, E. C.; Schofield, C. J. Dynamic combinatorial chemistry employing boronic acids/boronate esters leads to potent oxygenase inhibitors. Angew. Chem., Int. Ed. 2012, 51, 6672-6675, 10.1002/anie.201202000
56. Zervosen, A.; Herman, R.; Kerff, F.; Herman, A.; Bouillez, A.; Prati, F.; Pratt, R. F.; Frere, J. M.; Joris, B.; Luxen, A.; Charlier, P.; Sauvage, E. Unexpected tricovalent binding mode of boronic acids within the active site of a penicillin-binding protein. J. Am. Chem. Soc. 2011, 133, 10839-10848, 10.1021/ja200696y
57. Wayne, P. A. Performance Standards for Antimicrobial Susceptibility Testing, 27 th ed.; Clinical and Laboratory Standards Institute, 2017.
58. King, D.; Strynadka, N. Crystal structure of New Delhi metallo-beta-lactamase reveals molecular basis for antibiotic resistance. Protein Sci. 2011, 20, 1484-1491, 10.1002/pro.697
59. Adams, P. D.; Grosse-Kunstleve, R. W.; Hung, L.-W.; Ioerger, T. R.; McCoy, A. J.; Moriarty, N. W.; Read, R. J.; Sacchettini, J. C.; Sauter, N. K.; Terwilliger, T. C. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2002, 58, 1948-1954, 10.1107/S0907444902016657
60. Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and development of Coot. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 486-501, 10.1107/S0907444910007493